| 國家衛生研究院 |
2023-04-11 |
Carbohydrate antigen 19-9 response to initial adjuvant chemotherapy predicts survival and failure pattern of resected pancreatic adenocarcinoma but not which patients are suited for additional adjuvant chemoradiation therapy: From a prospective randomized
|
Chiu, YF;Liu, TW;Shan, YS;Chen, JS;Li, CP;Ho, CL;Hsieh, RK;Hwang, TL;Chen, LT;Ch'ang, HJ; Taiwan Cooperative Oncology Group pancreatic cancer study group, |
| 臺大學術典藏 |
2022-08-19T00:20:39Z |
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection
|
CHIUN HSU; Taiwan Cooperative Oncology Group; Liu T.-W.; Chen P.-J.; Cheng A.-L.; Lin J.; Yuan Q.; Xia N.; Yao M.; Lin S.-J.; Chen J.-H.; Chang C.-S.; Pei S.-N.; Tsou H.-H.; Yang H.-C. |
| 臺大學術典藏 |
2022-08-19T00:20:36Z |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
|
Cheng A.-L.; CHIUN HSU; Taiwan Cooperative Oncology Group; Chen P.-J.; Tsui C.-W.; Wu H.-Y.; Hsu Y.-T.; Chuang M.-H.; Hsiung C.A.; Liu T.-W.; Yang H.-C.; Hsiao C.-F.; Tsou H.-H. |
| 臺大學術典藏 |
2021-08-31T06:29:27Z |
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection
|
Yang H.-C.; Tsou H.-H.; Pei S.-N.; Chang C.-S.; Chen J.-H.; Yao M.; Lin S.-J.; Lin J.; Yuan Q.; Xia N.; Liu T.-W.; Chen P.-J.; ANN-LII CHENG; Hsu C.; Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2021-08-31T06:29:20Z |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
|
Tsou H.-H.; Yang H.-C.; Hsiao C.-F.; Hsiung C.A.; Liu T.-W.; Chuang M.-H.; Wu H.-Y.; Hsu Y.-T.; Tsui C.-W.; Chen P.-J.; ANN-LII CHENG; Hsu C.; Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2021-07-03T03:33:36Z |
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection
|
Yang H.-C.; Tsou H.-H.; Pei S.-N.; Chang C.-S.; Chen J.-H.; Yao M.; Lin S.-J.; Lin J.; Yuan Q.; Xia N.; Liu T.-W.; PEI-JER CHEN; Cheng A.-L.; Hsu C.; Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2021-07-03T03:33:29Z |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
|
Tsou H.-H.; Yang H.-C.; Hsiao C.-F.; Hsiung C.A.; Liu T.-W.; Chuang M.-H.; Wu H.-Y.; Hsu Y.-T.; Tsui C.-W.; PEI-JER CHEN; Cheng A.-L.; Hsu C.; Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2021-01-05T03:34:31Z |
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection
|
Taiwan Cooperative Oncology Group; Hsu C.; Cheng A.-L.; Chen P.-J.; Liu T.-W.; Xia N.; Yuan Q.; Lin J.; Lin S.-J.; MING YAO; Chen J.-H.; Chang C.-S.; Tsou H.-H.; Pei S.-N.; Yang H.-C. |
| 臺大學術典藏 |
2020-04-10T12:51:00Z |
Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection
|
Taiwan Cooperative Oncology Group; Chiun Hsu; Pei S.-N.; Chang C.-S.; Chen J.-H.; Yao M.; Lin S.-J.; Lin J.; Yuan Q.; Xia N.; Liu T.-W.; Chen P.-J.; Cheng A.-L.; Tsou H.-H.; Yang H.-C.; Yang H.-C.;Tsou H.-H.;Pei S.-N.;Chang C.-S.;Chen J.-H.;Yao M.;Lin S.-J.;Lin J.;Yuan Q.;Xia N.;Liu T.-W.;Chen P.-J.;Cheng A.-L.;Chiun Hsu;Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2020-04-10T12:50:59Z |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
|
Tsou H.-H.;Yang H.-C.;Hsiao C.-F.;Hsiung C.A.;Liu T.-W.;Chuang M.-H.;Wu H.-Y.;Hsu Y.-T.;Tsui C.-W.;Chen P.-J.;Cheng A.-L.;Chiun Hsu;Taiwan Cooperative Oncology Group; Tsou H.-H.; Yang H.-C.; Hsiao C.-F.; Hsiung C.A.; Liu T.-W.; Chuang M.-H.; Wu H.-Y.; Hsu Y.-T.; Tsui C.-W.; Chen P.-J.; Cheng A.-L.; Chiun Hsu; Taiwan Cooperative Oncology Group |
| 國家衛生研究院 |
2018-03-15 |
Quantification of HBV core antibodies may help predict HBV reactivation in lymphoma patients with resolved HBV infection
|
Yang, HC;Tsou, HH;Pei, SN;Chang, CS;Chen, JH;Yao, M;Lin, SJ;Lin, J;Yuan, Q;Xia, N;Liu, TW;Chen, PJ;Cheng, AL;Hsu, C; Taiwan Cooperative Oncology Group |
| 國家衛生研究院 |
2013-05 |
KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial
|
Chen, LT;Chen, JS;Chao, Y;Tsai, CS;Shan, YS;Hsu, C;Huang, SF;Tsou, HH;Lee, KD;Chiu, CF;Rau, KM;Ho, CL;Yu, MS;Taiwan Cooperative Oncology Group |
